MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.300
+0.010
+0.44%
After Hours: 2.300 0 0.00% 17:52 02/26 EST
OPEN
2.310
PREV CLOSE
2.290
HIGH
2.415
LOW
2.170
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
3.132
52 WEEK LOW
0.5801
MARKET CAP
344.98M
P/E (TTM)
-12.6862
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Analysts Offer Insights on Healthcare Companies: Lineage Cell Therapeutics (LCTX), Medtronic (MDT) and Cassava Sciences (SAVA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTX), Medtronic (MDT) and
SmarterAnalyst · 4d ago
H.C. Wainwright Sticks to Its Buy Rating for Lineage Cell Therapeutics (LCTX)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Cell Therapeutics (LCTX), with a price target of
SmarterAnalyst · 4d ago
Lineage Cell Therapeutics (LCTX) Gets a Buy Rating from Noble Financial
Noble Financial analyst Ahu Demir reiterated a Buy rating on Lineage Cell Therapeutics (LCTX) yesterday and set a price target of $4.00. The company's
SmarterAnalyst · 4d ago
H.C. Wainwright Keeps a Buy Rating on Lineage Cell Therapeutics (LCTX)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Cell Therapeutics (LCTX), with a price target of
SmarterAnalyst · 5d ago
Lineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021
Business Wire · 5d ago
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 02/19 20:15
Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical...
BusinessWire - BZX · 02/16 13:00
Lineage Cell extends gains after announcing collaboration with Neurgain
After an ~11.4% rise yesterday, Lineage Cell Therapeutics. (LCTX) is up ~6.7% in premarket hours today after the company announced an option and licensing agreement with Neurgain Technologies to test the latter’s Parenchymal Delivery
Seekingalpha · 02/09 14:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCTX stock price target is 5.20 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 44.27%
Shares Outstanding: 149.99M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Chief Financial Officer/Director
Brian Culley
Finance Director/Chief Accounting Officer/Controller
Alexandra Hernandez
Senior Vice President
Gary Hogge
General Counsel/Secretary
Chase Leavitt
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Stephen Farrell
Independent Director
Michael Mulroy
Independent Director
Angus Russell
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About LCTX
Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.